Q-T interval prolongation in cirrhosis: Relationship and severity

Abstract

Background: Cirrhosis as the final stage of progressive fibrosis of liver can affect other organs such as lungs, kidneys and heart. "Cirrhotic cardiomyopathy" involves the electrophysiological abnormalities such as QT interval prolongation. We assessed correlation between corrected QT interval prolongation and severity of cirrhosis based on Child Classification in each ECG lead.

Methods: In this case-control study, the patients attending the outpatient clinic and inpatient department of internal medicine of Velayat Hospital in Qazvin were enrolled from September 2014 to July 2015. Total samples were 74 patients, half of which were used as controls. Cirrhosis severity was determined as per Child Classification. Both groups had Ca2+, Mg2+, K+ tested and 12-lead ECG was obtained. The QT interval was corrected by two different formulas: (1) QTc=QT/√RR (QTc1); (2) QTc=QT+1.75 (heart rate-60) (QTc2). To analyze the data, the software SPSS Version 16 and Mann-Whitney, Pearson’s chisquare test-Kruskal-Wallis, and t-tests were used.

Results: The mean of QTc1 and QTc2 was longer in cirrhotics than the control group. There was a significant correlation between Child score and length of QTc1 in leads: III (p=0.032), AVL (p=0.041), V2 (p=0.049), V6 (p=0.015). There were significant differences in length of QTc1 in leads: V3 (p=0.031) and V6 (p=0.021); and QTc2 in lead V3 (p=0.039) between Child Classification.

Conclusions: Cirrhosis can induce QTc interval prolongation. Lead V3 has statistically significant correlation with the severity of cirrhosis based on child classification. We propose that QT interval prolongation be added as a criterion for prioritizing liver transplantation.

Keywords: Cardiomyopathy, Prolonged QT interval, Severity of cirrhosis, Child score

Citation:
Hajighamohammadi AA, Daee MM, Zargar A, et al. Q-T interval prolongation in cirrhosis: Relationship and severity. Caspian J Intern Med 2018; 9(3): 239-243.

Cirrhosis is the final stage of progressive fibrosis of liver which can also affect other organs such as the lungs, kidneys and heart simultaneously by poorly understood interactions. The term of "cirrhotic cardiomyopathy" was first used 20-30 years ago by 'Lee' (1) to point out the cardiac dysfunction in cirrhosis. In 2005, a panel of expert hepatologists and cardiologists met at the World Congress of Gastroentrology and suggested to adopt the definition of cirrhotic cardiomyopathy as a form of chronic cardiac dysfunction in patients with cirrhosis. This would be characterized by reduced contractile responsiveness to stress, and/or altered diastolic relaxation and/or electrophysiological abnormalities in the absence of other known cardiac disease (2). Thus a part of this definition also involves the electrophysiological abnormalities, which can be seen on an electrocardiogram (ECG). One of these ECG findings are the prolongation of QT interval (1). Prolongation of the QT interval reflects prolongation of ventricular repolarization period that may result in fatal arrhythmias (3).
Large studies, like Cardiovascular Health Study, the NHAMES study, the Strong Heart Study, Rotterdam and a recent meta-analysis have shown a correlation between the prolongation of QTc and cardiovascular mortality rate and sudden death in general population as a whole (4), but the relation between the prolonged QTc and cardiovascular events need to be further studied in cirrhotic patients. We believe that cirrhosis can induce prolongation of QT interval and the length of QT interval directly correlates with the severity of cirrhosis that is indicated in the Child Classification and prolonged corrected QT interval can predict a higher risk in these patients. This additional risk of prolonged QT interval potentially can be added to the criteria for prioritization of hepatic transplantation.

In the present study, we assessed the correlation between corrected QT interval prolongation and severity of cirrhosis based on Child Classification in each ECG lead.

**Methods**

In this case-control study, the patients attending the outpatient clinic and inpatient department of Internal Medicine of Velayat Hospital in Qazvin, were enrolled from September 2014 to July 2015. Total samples were 74 patients considered as the case (n=37) and control groups (n=37). In cirrhotic group (case), diagnosis was made on the basis of clinical, ultrasonography and histopathology and their severity was determined as per child scoring and classification system. Based on that, 12 patients were in class A, 12 in class B and 13 in class C. Also, on the same time frame, the control group was randomly selected from hospitalized patients at the same hospital, and did not have exclusion criteria. The control group was matched except for those with cirrhosis. In cirrhotics, serum albumin, prothrombin time, INR and total bilirubin were tested to determine their child score. Both groups had Ca\(^{2+}\), Mg\(^{2+}\), K\(^{+}\) tested.

Exclusion criteria from this study were: Serum calcium (Ca\(^{2+}\))<8.5 mg/dl (5) and/or serum potassium (K\(^{+}\)) <3.6 Mm (6) and/or serum magnesium (Mg\(^{2+}\))<1.8 meq/dl (7), any bundle branch block in ECG, past history of ischemic or non-ischemic heart disease and drug history which could prolong the QT interval such as: macrolides and quinolones, tricyclics and selective serotonin reuptake inhibitors, haloperidol and phenotiazine, ondansetron and prochlopeperazine (8). After the selection of samples, 12-lead ECG was obtained from both groups (speed was set at 25mm/s and amplitude of 10mm/mV). QT interval was measured manually from the onset of Q wave(or R) to the end of T wave. End of T wave was taken to be where its descending limb returns to baseline. Thereafter, the QT interval was corrected by the following two different formulas:

1. Bazetti’s formula or formula #1 as QTc = QT/√RR. Corrected QT interval from this formula is called QTc1 in our report.
2. Formula #2 as QTc = QT + 1.75 (heart rate-60) (QT as per millisecond). Corrected QT interval from this formula is called QTc2 in our report.

QTc longer than 0.45 second in females and 0.44 second in males were considered as prolonged by both formulas (4). To analyze the data, the following software and tests were used: the software SPSS16, Mann-Whitney test, t-test, Pearson-chi-square test and Kruskal-Wallis test. A p-value <0.05 was taken to be statistically significant.

**Results**

Data from 37 patients (21 males and 16 females) and 37 controls (24 males and 13 females) were analyzed. Range of age in patients with cirrhosis was between 28 to 84 years old with the mean of 58.75±11.47 years. Range of age in the control group was from 30 to 82 with the mean of 59.15±11.2 years. The two groups were matched according to age and gender (age: p=0.854, gender: p=0.475). The use of Mann-Whitney test showed that in all twelve leads, mean of QTc1 and QTc2 was longer in cirrhotic patients than that of the control group. The difference in these leads was statistically significant (table 1). By using the Pearson’s correlation test, there was a statistically significant correlation between Child score and length of QTc1 in leads: III (R: 0.354, p=0.032), AVL (R: 0.338, p=0.041), V2 (R: 0.326, p=0.049), V6 (R: 0.396, p=0.015). When we used Kruskal-Wallis test, there were statistically significant differences between Child Classification and length of QTc1 in leads: V3 (p=0.031) and V6 (p=0.021). Finally, by using Pearson [correlation between child score and length of QTc2 but by Kruskal-Wallis test, there was one shown in lead V3 (p=0.039). The number of patients with prolonged QTc1 was more in cirrhotic group as compared to the control group and this difference was statistically significant in all leads. But by using formula no.2, these differences were only statistically significant in leads: II, aVR, aVF, V3, V4, V5 and V6 (table 2).
Table 1. Mean and SD of QTc₁ and QTc₂ intervals per lead, in case (n=37) and control groups (n=37)

| Leads | QTc₁, mean±SD (per milisecond) | QTc₂, mean±SD (per milisecond) |
|-------|-------------------------------|-------------------------------|
|       | Case                          | Control                       | Case                          | Control                       | P-value*                  | Case                          | Control                       | P-value*                  |
| I     | 411±39                        | 391±28                        | 394±34                        | 377±23                        | 0.021                     | 394±34                        | 377±23                        | 0.016                     |
| II    | 420±43                        | 390±30                        | 403±38                        | 377±26                        | 0.002                     | 403±38                        | 377±26                        | 0.002                     |
| III   | 406±46                        | 383±26                        | 389±38                        | 370±22                        | 0.019                     | 389±38                        | 370±22                        | 0.025                     |
| aVR   | 426±47                        | 395±25                        | 410±37                        | 380±22                        | 0.002                     | 410±37                        | 380±22                        | 0.000                     |
| aVL   | 406±42                        | 385±29                        | 391±36                        | 372±24                        | 0.048                     | 391±36                        | 372±24                        | 0.023                     |
| aVF   | 420±39                        | 384±30                        | 401±33                        | 372±26                        | 0.000                     | 401±33                        | 372±26                        | 0.000                     |
| V1    | 410±34                        | 381±34                        | 394±27                        | 368±28                        | 0.001                     | 394±27                        | 368±28                        | 0.001                     |
| V2    | 421±41                        | 390±28                        | 403±34                        | 377±23                        | 0.000                     | 403±34                        | 377±23                        | 0.000                     |
| V3    | 427±43                        | 400±29                        | 407±35                        | 385±24                        | 0.002                     | 407±35                        | 385±24                        | 0.003                     |
| V4    | 431±39                        | 398±28                        | 412±33                        | 385±24                        | 0.000                     | 412±33                        | 385±24                        | 0.001                     |
| V5    | 423±45                        | 397±28                        | 408±38                        | 384±26                        | 0.005                     | 408±38                        | 384±26                        | 0.002                     |
| V6    | 421±40                        | 392±29                        | 405±34                        | 379±26                        | 0.001                     | 405±34                        | 379±26                        | 0.001                     |

*P-value <0.05 is statistically significant.

§ QTc₁ is corrected QT interval that calculated by formula No.1 as: QT/√RR. QTc₂ is corrected QT interval that calculated by formula No.2 as: QT(per millisecond)+1.75(Heart rate-60).

Table 2. Prolonged QTc₁ and QTc₂ interval per lead in case (n=37) and control group (n=37)

| Leads | Length of QT | QTc₁, mean±SD (per milisecond) | QTc₂, mean±SD (per milisecond) |
|-------|--------------|-------------------------------|-------------------------------|
|       |              | Case                          | Control                       | Case                          | Control                       | P-value*                  |
| I     | Normal       | 30 (81.1%)                    | 37 (100%)                     | 0.005                        | 36 (97.3%)                    | 37 (100%)                     | 0.314                     |
| II    | Prolonged    | 7 (18.9%)                     | -                             | 1 (2.7%)                      | -                             | 1 (2.7%)                      | -                         |
| III   | Normal       | 25 (67.6%)                    | 37 (100%)                     | 0.000                        | 33 (89%)                      | 37 (100%)                     | 0.040                     |
| aVR   | Prolonged    | 12 (32.47)                    | -                             | 4 (11%)                       | -                             | 4 (11%)                       | -                         |
| aVL   | Normal       | 28 (75.7%)                    | 37 (100%)                     | 0.001                        | 34 (91%)                      | 37 (100%)                     | 0.077                     |
| aVF   | Prolonged    | 9 (24.3%)                     | -                             | 3 (9%)                        | -                             | 3 (9%)                        | -                         |
| V1    | Normal       | 25 (67.6%)                    | 36 (97.3%)                    | 0.001                        | 32 (86%)                      | 37 (100%)                     | 0.021                     |
| V2    | Prolonged    | 12 (92.3%)                    | 1 (2.7%)                      | 5 (14%)                       | -                             | 5 (14%)                       | -                         |
| V3    | Normal       | 29 (78.4%)                    | 37 (100%)                     | 0.003                        | 36 (97%)                      | 37 (100%)                     | 0.314                     |
| V4    | Prolonged    | 8 (21.6%)                     | -                             | 1 (3%)                        | -                             | 1 (3%)                        | -                         |
| V5    | Normal       | 29 (78.4%)                    | 37 (100%)                     | 0.003                        | 33 (89%)                      | 37 (100%)                     | 0.040                     |
| V6    | Prolonged    | 8 (21.6%)                     | -                             | 4 (11%)                       | -                             | 4 (11%)                       | -                         |

*P-value <0.05 is statistically significant.

¶ QTc₁ is corrected QT interval that calculated by formula No. 1 as: QT/√RR. QTc₂ is corrected QT interval that calculated by formula No.2 as: QTc₂=QT(per millisecond)+1.75(Heart rate-60).

§ QTc₁ and QTc₂ higher than 0.450 second for females and higher than 0.440 second in males were considered prolonged.
Discussion

In the present study, we assessed correlation between corrected QT interval prolongation and severity of cirrhosis based on Child Classification in each ECG lead. Results showed that mean of QTc₁ and QTc₂ were longer in cirrhotics than control group. There was a significant correlation between Child score and length of QTc in leads: III, AVL, V2, V6. Besides, there were significant differences in length of QTc₁ in leads: V3 and V6; and QTc₂ in lead V3 between Child Classification.

In a study done in 2003 by Midis et al., 52 cirrhotic patients were entered into a study where the severity of cirrhosis was scored by Child-Pugh classification (9). In that study, QTc was longer in cirrhotic group as compared to the control group (0.471 second, P=0.0007 and 0.461 second, P=0.0017) and prolongation of QTc in cirrhotic patients had a correlation with the Child B and C classification which was statistically significant (0.489 second, p=0.001 and 0.480 second, p=0.0002) but not so in child A classification in cirrhotics (0.445 second, p=0.4366). In another study done by Patel D et al. in 2014, a number of 51 cirrhotic patients were without heart disease. In this study, prolonged QT was associated with worse liver function (higher INR, lower albumin) (10).

In the study done in Romania in 2011 (11), there was a statistically significant correlation with the QTc and Child Classification. QTc was significantly longer in class C patients (520±45 milliseconds) compared with those in class “A” in cirrhotics (462±25 milliseconds; p=0.027). In study by Marafioti V et al. in 2015, QT interval prolongation was strongly associated with hepatic encephalopathy (12). In previous studies done on the correlation between QT interval prolongation and cirrhosis, only Bazett’s formula was used. This formula has a low accuracy. More than 30% of normal ECGs have been reported as having prolonged QT with this formula. This is because it overcorrects the QT interval in low heart rate and undercorrects it in higher heart rates (13).

In our study, we corrected QT interval with 2 formulas; first, the Bazette formula as: QTc=QT/√RR and second formula as: QTc=QT+1.75 (heart rate-60) (per millisecond). The latter formula is the newest formula recommended by Joint Committee of Professional Organization. This formula is a linear formula which is less affected by patient’s heart rate (13). Therefore, in our opinion, the results of present study are more accurate than previous studies about corrected QT interval prolongation and cirrhosis.

The current study showed that not only cirrhosis can induce QT interval prolongation but also in lead V3, the prolongation of QT interval directly correlates with the severity of cirrhosis based on Child classification using both formulas (QTc₁: P=0.031, QTc₂: P=0.039).

Unlike in general population and patients with ischemic heart disease, the pathophysiology and complication of prolonged QT in cirrhotic patients is poorly understood. It may turn out that, cirrhotics may be more resistant to complication of QT interval prolongation by unknown mechanism in comparison with general population and patients with ischemic heart disease, although in a study by Kim SM et al. in 2017, QT interval prolongation in cirrhotic patients increased the risk of mortality (14).

Until further studies are done, there should be efforts to avoid factors which would contribute to this prolongation. For example, fluoroquinolones are used widely for urinary tract infection (UTI) and prophylaxis of spontaneous bacterial peritonitis (SBP) in cirrhotics can induce QT interval prolongation; therefore, these medications should be used with caution if absolutely indicated. Likewise, electrolyte imbalance like hypokalemia, hypocalcemia and hypomagnesemia which could result to diuretics and malnutrition should be vigorously corrected. We believe that more attention should be given to QT interval prolongation at pre, pri, and postoperative care of cirrhotics undergoing liver transplantation. Hence during cardiovascular assessment, to determine the cardiac risk of liver transplantation, physicians should pay more attention to QT interval prolongation at pre-, peri- and postoperative care of cirrhotic patients.

This study has several limitations. First, it was basically a cross-sectional study, and unfortunately, we did not access to ECG before cirrhosis and after liver transplantation. As a result, we could not evaluate the degree of QT lengthening in correlation with cirrhosis and liver transplantation. Second, besides the severity of cirrhosis, the etiology of cirrhosis may influence the length of QT interval. This however was not evaluated in our study. In total, cirrhosis can induce QTc interval prolongation. In Patel D et al.’s study in 2014, besides the other known factors affecting repolarization, cirrhosis can affect ventricular repolarization and induced prolonged QT (10). In another study by Young Huh et al. in 2014, QT interval in child class C patients was longer than child class A patients (15). Lead V3 has statistically significant correlation with the severity of cirrhosis based on
child classification in both formulas used. (QTc₁: p=0.031, QTc₂: p=0.039). Perhaps, QT interval prolongation can be a prognostic factor in more advanced cirrhosis with higher risk. As a consequence, we propose that QT interval prolongation be added as a criterion for prioritizing liver transplantation.

In conclusion, cirrhosis can induce QTc interval prolongation. Lead V3 has statistically significant correlation with the severity of cirrhosis based on Child Classification.

Acknowledgments
Hereby, all authors are very grateful for the kind and valuable cooperation of Dr. Arshia Noori, Dr. Habib Rahban, and staff of Clinical development research unit of Velayat Hospital in preparing this article.

Funding: No funding was provided in this study.
Conflict of interest: There is no conflict of interest in this study.

References
1. Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009; 3: 294-304.
2. Moller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008; 57: 268-78.
3. Zurick AO, Spier BJ, Teelin TC, et al. Alterations in corrected QT interval following liver transplant in patient with end-stage liver disease. Clin Cardiol 2010; 33: 672-7.
4. Hung CS, Tseng PH, Tu CH, et al. Nonalcoholic fatty liver disease is associated with qt prolongation in the general population. J Am Heart Assoc 2015; 4. pii: e001820. doi: 10.1161/JAHA.115.001820.
5. Potts JT, Juppner H. Pathophysiology of hypocalcemia: classification based on mechanism. In: kasper DL, et al (eds): Harrison's principles of internal medicine. 18th ed. New York: McGraw-Hill 2012; p: 3113.
6. Mount DB. Hypokalemia. In: Kasper DL, et al (eds): Harrison's principles of internal medicine.18th ed. New York: McGraw-Hill 2012; p: 351.
7. Assadi F. Hypomagnesemia: an evidence-based approach to clinical cases. Iran J Kidney Dis 2010; 4: 9-13.
8. Ayad RF, Assar MD, Simpson L, Garner JB, Schussler JM. Causes and management of drug-induced long QT syndrome. Proc (Bayluniv Med Cent) 2010; 23: 250-5.
9. Mimidis K, PapadopoulosV, Thomopoulos K, et al. Prolongation of the QTc interval in patients with cirrhosis. Ann Gastroenterol 2003; 16: 155-8.
10. Patel D, Singh p, Katz W, et al. QT interval prolongation in end-stage liver disease cannot be explained by nonhepathic factors. Ann Noninvasive Electrocardiol 2014; 19: 574-81.
11. Mozos I, Costea C, Serban C, Susan L. Factors associated with a prolonged QT interval in liver cirrhosis patients. J Electrocardiol 2011; 44: 105-8.
12. Marafioti V, Benetti V, Montin U, et al. QTc interval prolongation and hepatic encephalopathy in patients candidate for liver transplantation: A valid inference? Int J Cardiol 2015; 188: 43-4.
13. Mirvis DM, Goldberger AL. QT interval. In: Bonow RO, et al (eds): Braunwald’s heart disease. 9th ed. Philadelphia/China: Elsevier 2015; p: 124.
14. Kim SM, George B, Alcivar-Franco D, et al. QT prolongation is associated with increased mortality in end stage liver disease. World J Cardiol 2017; 9: 347-54.
15. Huh IY, Park ES, Kim KI, et al. Alteration of the QT variability index in end stage liver disease. Korean J Anesthesiol 2014; 66: 199-203.